-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2023-507396-21-00
4
2023-03-16
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
-
2022-502328-35-00
4
2023-01-30
Alpha (α)-thalassemia
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-520108-25-00
4
2025-11-05
Non-small cell lung cancer (NSCLC)
-
2024-516745-39-00
4
2025-07-11
Cutaneous lupus erythematosus
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2022-501483-18-00
10
2025-03-28
Advanced Non-Small Cell Lung Cancer
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-515089-15-00
5
2025-02-28
active non-infectious uveitis (intermediate uveitis, posterior uveitis
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-509069-19-00
4
2024-12-12
idiopathic pulmonary fibrosis
-
2023-504359-29-01
5
2024-12-11
Multiple sclerosis
-
2024-514343-29-00
5
2024-11-19
multiple sclerosis
-
2024-515870-28-00
5
2024-10-22
Moderate to severe systemic lupus erythematosus
-
2023-503714-77-00
4
2024-10-01
Advanced Non-Small Cell Lung Cancer
-
2024-511705-31-00
5
2024-09-26
Arterial Hypertension
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-503923-24-00
5
2024-07-22
Sjögren’s Syndrome With Moderate-toSevere Symptom State
-
2023-505435-12-00
5
2024-06-04
Asthma